Investors are rushing into the relative safe-haven of the bond market, causing the yield on the U.S. 10-year Treasury to plummet.Real Estateread more
Stocks fell sharply on Thursday as investors started to fear the U.S.-China trade war is slowing the economy.Marketsread more
Wall Street is becoming convinced that both the White House and Beijing are willing to engage in a protracted trade war that could begin to hit consumers and slow global...Market Insiderread more
See which stocks are posting big moves after the bell on Thursday, May 23.Market Insiderread more
Investors rushed into the safety of bonds Thursday and sold stocks, as it appeared the trade war could be prolonged and more painful for the world economy than expected.Market Insiderread more
Oracle co-founder Larry Ellison disclosed a $1 billion stake in Tesla in late December. It's now worth about $580 million.Technologyread more
Investors trying to get a gauge on the state of U.S.-China trade relations should look at shares of big chipmakers, according to Ned Davis Research.Marketsread more
The volatile stock of Tesla has lost over 40% so far this year, and experts are split on what might happen next.Trading Nationread more
The president addressed farmers and ranchers hurt by the trade war with China, just hours after his administration announced a new $16 billion farm and ranch aid package for...Politicsread more
The e-mail's optimistic tone helped Tesla shares turn positive for the first time in seven days.Technologyread more
J.P. Morgan Chase has cut ties with Purdue Pharma LP over the OxyContin maker's alleged role in the U.S. opioid crisis, forcing it to find a new bank to manage cash and bill...Banksread more
Mikael Dolsten, the U.S. pharma giant's head of research and development, said the deal would offer "much more value for patients and health care providers" in a video posted on the company's website Monday morning.
His remarks are an attempt to address concerns that Pfizer's main motivation for buying AstraZeneca is tax avoidance.
Meanwhile, their prey bolstered the case for remaining independent by announcing positive results for a new treatment for skin condition psoriasis. The U.K. based pharma company is also expected to announce clinical trial results for some of its most promising new medicines later in the week, ahead of key medical conferences later this month.
Ian Read, chief executive of the U.S. pharma giant, and Pascal Soriot, his opposite number at AstraZeneca, will both appear in front of U.K. members of parliament on Tuesday morning. Read will have to address mounting opposition to the deal from U.K. politicians.
Pfizer has two weeks from Monday to come back with a third bid for the smaller U.K. company, which would be big enough to bring management to the table and win over shareholders.
Prime Minister David Cameron told the BBC on Sunday the government had made "good progress" on securing commitments from Pfizer to keeping jobs in the U.K. - but added the government still wants "more."
One point Pfizer executives are likely to be pushed on is whether they could make a 10 year, rather than a 5 year, commitment to U.K. science jobs. A longer commitment before they do due diligence on AstraZeneca is unlikely, according to a source close to the company.
Read said the deal would be a "win-win" for shareholders and patients in a video posted on the Pfizer website Saturday morning.
The U.K. politicians he will appear in front of Tuesday will put him through his paces on what a completed deal might mean for the U.K. economy and science base. A meeting with Ed Miliband, the U.K. Labour Party leader who has led criticism of Pfizer's record, could be back on the cards. Miliband earlier turned down a meeting because of the European election campaign.